Cita APA (7a ed.)

TA, B., MW, M., LB, L., JM, O., DM, M., RE, F., . . . RA, S. (2021). Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia. Dove Medical Press.

Cita Chicago Style (17a ed.)

TA, Berger, Manry MW, Lindsell LB, Osher JM, Miller DM, Foster RE, Riemann CD, Petersen MR, y Sisk RA. Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia. Dove Medical Press, 2021.

Cita MLA (8a ed.)

TA, Berger, et al. Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia. Dove Medical Press, 2021.